Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Access the Safety/Efficacy of Thalidomide in the Treatment of Anemia in Patients With Myelodysplastic Syndromes

NCT00050843 is registered in ClinicalTrials.gov with Celgene Corporation as lead sponsor.

NCT NCT00050843
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00050843 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Access the Safety/Efficacy of Thalidomide in the Treatment of Anemia in Patients With Myelodysplastic Syndromes
Lead sponsor
Celgene Corporation
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2001
Completion date
February 29, 2004
Enrollment
220
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndromes